Compare WTS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTS | NUVL |
|---|---|---|
| Founded | 1874 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.1B |
| IPO Year | 1986 | 2021 |
| Metric | WTS | NUVL |
|---|---|---|
| Price | $278.75 | $104.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $271.40 | $134.29 |
| AVG Volume (30 Days) | 157.4K | ★ 818.0K |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 16.19 | N/A |
| EPS | ★ 9.69 | N/A |
| Revenue | ★ $2,353,800,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | $28.68 | ★ N/A |
| Revenue Growth | ★ 4.18 | N/A |
| 52 Week Low | $177.59 | $55.54 |
| 52 Week High | $287.89 | $112.88 |
| Indicator | WTS | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 52.26 |
| Support Level | $266.50 | $103.83 |
| Resistance Level | $281.60 | $107.99 |
| Average True Range (ATR) | 5.40 | 3.38 |
| MACD | 0.75 | -0.87 |
| Stochastic Oscillator | 84.20 | 12.44 |
Watts Water Technologies Inc is a U.S.-based company that provides safety, energy efficiency, and water conservation products. Its product portfolio includes residential and commercial flow control products, which are sold for plumbing and hot water applications; HVAC and gas products, including commercial boilers, water heaters, heating solutions, etc.; drainage and water reuse products, including drainage products and engineered rainwater-harvesting solutions; and water quality products, including point-of-use and point-of-entry water filtration, conditioning, and scale prevention systems. Its products are marketed through brands like Watts, Apex, Bradley, Nexa, and others. Geographically, the company derives its key revenue from the Americas, followed by Europe and the APMEA region.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.